Assessment of psoriasis severity in Brazilian patients with chronic plaque psoriasis attending outpatient clinics: a multicenter, population-based cross-sectional study (APPISOT)

Imagem de Miniatura
Arquivos
art_ROMITI_Assessment_of_psoriasis_severity_in_Brazilian_patients_with_2018.PDF (1.63 MB)
Citações na Scopus
12
Tipo de produção
article
Data de publicação
2018
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
TAYLOR & FRANCIS LTD
Autores
FABRICIO, Lincoln Helder Zambaldi
SOUZA, Cacilda da Silva
GALVAO, Leticia Oba
CASTRO, Caio Cesar Silva de
TERENA, Aripuana Coberio
CARNEIRO, Francisca Regina Oliveira
OYAFUSO, Luiza Keiko Matsuka
CARNEIRO, Sueli
GONTIJO, Bernardo
Citação
JOURNAL OF DERMATOLOGICAL TREATMENT, v.29, n.8, p.775-785, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Purpose: Data on chronic plaque psoriasis severity and its potential clinical and lifestyle implications in the Brazilian population are limited. The primary aim of this study was to assess the clinical severity of plaque psoriasis in Brazil. Further objectives included evaluating potential associations between disease severity and demographic, lifestyle, and clinical characteristics, health-related quality of life (HRQOL), and work productivity. Materials and methods: This observational (non-interventional) cross-sectional study was conducted in 26 dermatologic clinics across 11 Brazilian states. Psoriasis severity was assessed using investigator judgment and Finlay's Rule of Tens: a Psoriasis Area and Severity Index (PASI) score >10, a Body Surface Area (BSA) > 10%, or a Dermatology Life Quality Index (DLQI) score >10. Results: Among 1125 patients, 205 (18.2%) had moderate-to-severe disease. On multiple regression analyses, psoriasis severity was significantly (directly) associated with the presence of physical inactivity and comorbid pain, anxiety, and depression; and significantly (inversely) associated with HRQOL and work productivity. Limitations: Cross-sectional studies cannot assess temporal trends, and observational studies cannot conclusively determine causality or exclude biases and confounding due to unmeasured variables. Conclusions: Among Brazilian patients with moderate-to-severe psoriasis, disease severity had far-reaching adverse impacts on lifestyle, comorbidities, HRQOL, and work productivity.
Palavras-chave
Epidemiology, health-related quality of life, pain, psoriasis, severity, worker productivity
URI
https://observatorio.fm.usp.br/handle/OPI/30157
Referências
  1. Armstrong AW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052935
  2. Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3
  3. Christophers E, 2001, CLIN EXP DERMATOL, V26, P314, DOI 10.1046/j.1365-2230.2001.00832.x
  4. COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104
  5. DAUT RL, 1983, PAIN, V17, P197, DOI 10.1016/0304-3959(83)90143-4
  6. Ferraz LB, 2006, QUAL LIFE RES, V15, P565, DOI 10.1007/s11136-005-2638-9
  7. Ferreira CP, 2010, ACTAS DERMO-SIFILOGR, V101, P230, DOI 10.1016/j.ad.2009.09.008
  8. Ferreira KA, 2011, SUPPORT CARE CANCER, V19, P505, DOI 10.1007/s00520-010-0844-7
  9. Finlay AY, 2005, BRIT J DERMATOL, V152, P861, DOI 10.1111/j.1365-2133.2005.06502.x
  10. FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x
  11. FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839
  12. Griffiths CEM, 2007, LANCET, V370, P263, DOI 10.1016/S0140-6736(07)61128-3
  13. Horn EJ, 2007, J AM ACAD DERMATOL, V57, P957, DOI 10.1016/j.jaad.2007.06.042
  14. Horn EJ, 2007, J AM ACAD DERMATOL, V57, P963, DOI 10.1016/j.jaad.2007.07.023
  15. Katugampola RP, 2007, BRIT J DERMATOL, V156, P945, DOI 10.1111/j.1365-2133.2007.07817.x
  16. Krueger G, 2001, ARCH DERMATOL, V137, P280
  17. KRUSKAL WH, 1952, J AM STAT ASSOC, V47, P583
  18. MANN HB, 1947, ANN MATH STAT, V18, P50, DOI 10.1214/aoms/1177730491
  19. Marcolino José Álvaro Marques, 2007, Rev. Bras. Anestesiol., V57, P52, DOI 10.1590/S0034-70942007000100006
  20. Martins Gladys Aires, 2004, An. Bras. Dermatol., V79, P521, DOI 10.1590/S0365-05962004000500002
  21. MASUR J, 1983, BRAZ J MED BIOL RES, V16, P215
  22. Nestle FO, 2009, NEW ENGL J MED, V361, P496, DOI 10.1056/NEJMra0804595
  23. Olsson I, 2005, BMC PSYCHIATRY, V5, DOI 10.1186/1471-244X-5-46
  24. Pais-Ribeiro J, 2007, Psychol Health Med, V12, P225, DOI 10.1080/13548500500524088
  25. Phan C, 2016, ANN DERMATOL VENER, V143, P264, DOI 10.1016/j.annder.2015.06.024
  26. Quaresma MR, 1999, REV BRAS REUMATOL, V39, P143, DOI 10.1590/S0482-50042010000300005
  27. Romiti R, 2017, INT J DERMATOL, V56, pE167, DOI 10.1111/ijd.13604
  28. Sampogna F, 2004, J INVEST DERMATOL, V122, P602, DOI 10.1046/j.0022-202X.2003.09101.x
  29. Schoffski Oliver, 2007, J Dtsch Dermatol Ges, V5, P209, DOI 10.1111/j.1610-0387.2007.06240.x
  30. Schon MP, 2005, NEW ENGL J MED, V352, P1899, DOI 10.1056/NEJMra041320
  31. Sohn S, 2006, DERMATOLOGY, V212, P137, DOI 10.1159/000090654
  32. Spearman C, 2010, INT J EPIDEMIOL, V39, P1137, DOI 10.1093/ije/dyq191
  33. WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
  34. Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007
  35. Yeung H, 2013, JAMA DERMATOL, V149, P1173, DOI 10.1001/jamadermatol.2013.5015
  36. Yu AP, 2009, CURR MED RES OPIN, V25, P2429, DOI 10.1185/03007990903185557
  37. ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/50